The formal recognition of obesity as a disease has fundamentally accelerated pharmaceutical development and transformed access pathways for weight management therapies. Insurance coverage and reimbursement mechanisms—previously unavailable—now enable broader treatment deployment, particularly for GLP-1 receptor agonists and similar agents.
However, this shift raises critical questions about the interplay between clinical benefit and commercial incentive. Drawing parallels to the antidepressant revolution of the 1990s, Max Moser’s analysis in STAT News demonstrates that disease classification consistently precedes market expansion across therapeutic domains. While legitimising pharmaceutical intervention can expand access for patients who need it, the same framing mechanisms may also drive overtreatment and inequitable distribution of benefits across populations.
Clinicians and policymakers must carefully distinguish between genuine therapeutic advancement and classification decisions shaped primarily by financial incentives.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: Obesity as disease: Who profits from the classification shift? →
